<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959542</url>
  </required_header>
  <id_info>
    <org_study_id>13-343</org_study_id>
    <secondary_id>U01CA151261</secondary_id>
    <nct_id>NCT01959542</nct_id>
  </id_info>
  <brief_title>Early Changes In Multiparametric MRI In Prostate Cancer</brief_title>
  <official_title>Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study, the investigators are trying to determine if there are measurable
      changes in prostate MRI that will help predict those who will or will not respond to Androgen
      Deprivation Therapy (ADT) and External Beam Radiation Therapy (EBRT) The first baseline
      prostate MRI prior to the start of treatment is standard of care. The participant's ADT/EBRT
      treatment is also standard of care, as advised by their doctor. It is the 3 follow up
      prostate MRIs during ADT/EBRT treatment, and 4 follow up serum PSA levels that are part of
      this research study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If the participant chooses to take part in this research study, the participant will have 3
      follow up prostate MRIs during a 6 month time period, while the participant is having their
      ADT/EBRT treatment. These follow-up prostate MRIs will use a standard imaging protocol
      without the use of an endorectal coil. The participant will also have a total of 4 blood
      samples to measure serum PSA. 1-2 mls (just less than ½ teaspoon) will be taken for each
      sample.

      Research Study Plan

        -  Baseline Visit (routine standard of care screening visit): PSA blood test and prostate
           MRI

        -  Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI

        -  Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI

        -  Visit 3 (on last day of EBRT): PSA blood test

        -  Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI

      Planned Follow-up: The investigator would like to keep track of the participant's prostate
      cancer status while they continue to see their doctor at DFCI. The investigators would like
      to do this by collecting the following data from the participant's medical records, to look
      at long-term outcome of their ADT/EBRT treatment.

        -  PSA values

        -  Clinical results of your treatment. The investigator will not contact the participant to
           obtain this information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation Between MRI Parameter at Visit 1 and Nadir PSA</measure>
    <time_frame>2 months after starting ADT (Visit 1)</time_frame>
    <description>Pearson correlation coefficient between MRI parameters at visit 1 and nadir PSA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation Between MRI Parameter at Visit 2 With Nadir PSA</measure>
    <time_frame>6 weeks after starting EBRT (Visit 2)</time_frame>
    <description>Pearson correlation coefficient between MRI parameters at visit 2 with nadir PSA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MRIs and PSA Blood Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI
Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI
Visit 3 (on last day of EBRT): PSA blood test
Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>MRIs and PSA Blood Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PSA Blood Test</intervention_name>
    <description>Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.</description>
    <arm_group_label>MRIs and PSA Blood Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males with unfavorable intermediate- to high-risk localized disease, defined as
             having one of the following three categories, Clinical or radiographic T2b-T4 primary
             tumor or Gleason score 7-10 in any core, or PSA ≥ 10 prior to initiation of therapy

          -  Patients are deemed suitable for therapy with ADT and EBRT.

          -  Subjects must to able to provide informed written consent prior to study entry.

        Exclusion Criteria:

          -  The standard exclusion criteria for MRI exams will apply which include patients with
             pacemakers, non-compatible intra-cranial vascular clips, inner ear implants, and
             severe claustrophobia.

          -  Patients who because of age, general medical or psychiatric condition, or physiologic
             status unrelated to the presence of prostate cancer are unlikely to be candidates for
             repeat MRIs, or cannot give valid informed consent.

          -  Patients unwilling or unable to undergo the multiparametric MRI exam (non-endorectal
             coil).

          -  Patients with a history of allergic reaction to latex or Gadolinium containing
             intravenous contrast agents.

          -  Individuals with renal disease or other contraindications to gadolinium will be
             excluded. The BWH standard MRI contrast screening criteria will be used to establish
             renal status.

          -  Patients who have had prior prostatectomy or prior androgen therapy.

          -  Patients with hip implant or any other metallic implant or device that results in
             significant distortion of the local magnetic field and compromise of the quality of
             the multiparametric MRI data.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiona Fennessy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <results_first_submitted>February 6, 2019</results_first_submitted>
  <results_first_submitted_qc>April 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2020</results_first_posted>
  <disposition_first_submitted>June 29, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 12, 2018</disposition_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Fiona Fennessy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01959542/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>All enrolled patients undergo PSA sampling and prostate MRI. No control arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MRIs and PSA Blood Test</title>
          <description>Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI
Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI
Visit 3 (on last day of EBRT): PSA blood test
Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI
MRI
PSA Blood Test: Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
Androgen Deprivation Therapy (ADT): Patients will receive ADT as part of their standard clinical care, as determined by their clinician.
External Beam Radiation Therapy (EBRT): Patients will receive EBRT as part of their standard clinical care, as determined by their clinician.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>mean</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>baseline PSA</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.75" spread="32.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between MRI Parameter at Visit 1 and Nadir PSA</title>
        <description>Pearson correlation coefficient between MRI parameters at visit 1 and nadir PSA</description>
        <time_frame>2 months after starting ADT (Visit 1)</time_frame>
        <population>12 patients enrolled. For one patient, data was not extracted from the MRI due to artifact.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>All enrolled patients undergo PSA sampling and prostate MRI. No control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between MRI Parameter at Visit 1 and Nadir PSA</title>
          <description>Pearson correlation coefficient between MRI parameters at visit 1 and nadir PSA</description>
          <population>12 patients enrolled. For one patient, data was not extracted from the MRI due to artifact.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" lower_limit="-0.86" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Pearson's product-moment correlation</non_inferiority_desc>
            <p_value>0.09</p_value>
            <method>Pearson’s product-moment correlation</method>
            <param_type>Pearson’s product-moment correlation</param_type>
            <param_value>-0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-086</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between MRI Parameter at Visit 2 With Nadir PSA</title>
        <description>Pearson correlation coefficient between MRI parameters at visit 2 with nadir PSA</description>
        <time_frame>6 weeks after starting EBRT (Visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRIs and PSA Blood Test</title>
            <description>All enrolled patients undergo PSA sampling and prostate MRI. No control arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between MRI Parameter at Visit 2 With Nadir PSA</title>
          <description>Pearson correlation coefficient between MRI parameters at visit 2 with nadir PSA</description>
          <units>Pearson correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-0.88" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Pearson’s product-moment correlation</method>
            <method_desc>Pearson's product moment correlation</method_desc>
            <param_type>Pearson’s product-moment correlation</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During and immediately after the MRIs.</time_frame>
      <desc>Adverse events included any serious events related to the MRI exam. Expected adverse events from MRI are not serious and include claustrophobia while in the MRI magnet, a warming sensation while in the MRI magnet, or infiltration of intravenous contrast in the subcutaneous tissues at the time of its administration.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>All enrolled patients undergo PSA sampling and prostate MRI. No control arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fiona Fennessy</name_or_title>
      <organization>Brigham and Women's Hospital/Dana-farber Cancer Institute</organization>
      <phone>617 632 4891</phone>
      <email>ffennessy@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

